The overall aim of the CRC is to achieve progress in lymphoma therapy. Therefore, the members of the CRC aim to investigate key cellular mechanisms involved in B cell lymphomagenesis and therapy resistance, since these processes are complex. In order to support these aims, a central platform will be established for the multiparametric analysis of human and murine samples. It will provide cytometric, immunohistochemical, (epi-)genomic and proteomic analytics to all participants of the CRC to dissect the diversity of the malignant and non-malignant counterparts in lymphoid malignancies at bulk and single cell level by applying standardized protocols for the reproducible and reliable assessment and phenotyping of lymphoma. A close cooperation with the platform Z03 will allow to share, visualize, and inter-relate data.
PRINCIPAL INVESTIGATOR
Department of Medicine II
Hematology/Oncology
University Hospital Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Department of Translational Genomics
CMMC - Center for Molecular Medicine Cologne
University of Cologne
Robert-Koch-Straße 21
50931 Cologne
University of Cologne
Weyertal 115b
50931 Cologne
Apoptosis-Signaling and Therapy Resistance Group
Department I of Internal Medicine
University Hospital of Cologne
Kerpener Straße 62
50937 Cologne